ERBB2 and ductal breast carcinoma in situ: The amplification and overexpression of HER2 is seen more frequently in DCIS (50–60%) [23] than in invasive ductal carcinoma of the breast (10–20%) and the presence of DCIS can thereby bias MLPA results.